ŌNŌCOR has announced the first-in-human use of the catheter-based ŌNŌ endovascular retrieval system for the percutaneous removal of an intracardiac tumour, a process which normally requires open-heart surgery.

The new retrieval system has been designed for receiving, aligning, compressing and percutaneously removing non-biologic and biologic material from the vascular system.

ŌNŌCOR stated that the ŌNŌ system is simple to use and compatible with endovascular snares, vascular sheaths and other graspers that are available commercially.

It has been developed to make catheter-based retrieval quick and safe, as well as to eliminate the need for remedial surgical procedures.

At the University of Washington (UW) Medical Center in Seattle, Washington, US, Dr James McCabe and Zachary Steinberg, along with their team, used the ŌNŌ and electrocautery to snare, resect and remove a cardiac fibromyxoma from the right atrium of a 54-year-old patient.

The procedure provides access to a new therapy for heart mass patients across the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

UW Interventional Cardiology section chief Dr McCabe said: “Intracardiac tumours are a vexing problem and present a management dilemma for physicians. These tumours are often found incidentally by echocardiography at relatively small sizes.

“However, rather than subjecting patients to elective surgical removal, these masses are typically followed expectantly until they increase in size to a point where they are physiologically problematic. At that point, the risks of open-heart surgery are deemed justifiable.”

In May, the ŌNŌ retrieval system received 510(k) clearance from the US Food and Drug Administration (FDA).

The company noted that the device is currently available at a few sites across the US.